In the latest revision of the HF guidelines by the American College of Cardiology and the American Heart Association, sodium-glucose cotransporter 2 inhibitors (SGLT2i) were included in guidelines-directed medical therapy for HF with reduced, mildly reduced, and preserved EF.43 The gene discussed is SLC5A2; the disease is hydrops fetalis.